Skip to main content Back to Top
Advertisement

9/28/2026

Amoxicillin and Clavulanate Oral Presentations

Products Affected - Description

    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 50 mL bottle, 1 count, NDC 00143-9981-50
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 50 mL bottle, 1 count, NDC 00143-9982-50
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9982-75
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9853-75
    • Amoxicillin and Clavulanate oral tablet, Hikma, 875 mg/125 mg, 20 count, NDC 00143-9249-20
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 50 mL bottle, 1 count, NDC 00781-6102-52
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 875 mg / 125 mg, 100 count, NDC 00781-1852-01 - discontinued
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00093-2277-73
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00093-2279-73
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00093-8675-75
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00093-8675-74
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00093-8675-78
    • Amoxicillin and Clavulanate oral tablet, Teva, 200 mg/28.5 mg, 20 count, NDC 00093-2270-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 400 mg/57 mg, 20 count, NDC 00093-2272-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 500 mg/125 mg, 20 count, NDC 00093-2274-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 875 mg/125 mg, 20 count, NDC 00093-2275-34

Reason for the Shortage

    • Aurobindo refuses to provide availability information.
    • As of August 1, 2026, Chartwell purchased a beta-lactam manufacturing facility from Teva. Products manufactured at this site include multiple dosage forms of amoxicillin, amoxicillin/clavulanate, dicloxacillin, and oral penicillin. Chartwell has all amoxicillin and clavulanate presentations available.
    • Hikma did not provide a reason for the shortage.
    • Micro Labs was not available to provide information.
    • Sandoz did not provide a reason for the shortage.
    • Teva sold its beta lactam manufacturing facility to Chartwell. Teva is discontinuing its beta-lactam product line, including amoxicillin and clavulanate, over the coming months.
    • US Antibiotics has amoxicillin and clavulanate oral suspension available.
    • Wockhardt discontinued amoxicillin and clavulanate oral presentations in October 2024.

Available Products

    • Amoxicillin and Clavulanate oral chewable tablet, Chartwell, 200 mg/28.5 mg, 20 count, NDC 62135-0104-20
    • Amoxicillin and Clavulanate oral chewable tablet, Chartwell, 400 mg/57 mg, 20 count, NDC 62135-0105-20
    • Amoxicillin and Clavulanate oral powder for suspension, Chartwell, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 62135-0093-01
    • Amoxicillin and Clavulanate oral powder for suspension, Chartwell, 200 mg/5 mL - 28.5 mg/5 mL, 50 mL bottle, 1 count, NDC 62135-0093-50
    • Amoxicillin and Clavulanate oral powder for suspension, Chartwell, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 62135-0094-01
    • Amoxicillin and Clavulanate oral powder for suspension, Chartwell, 400 mg/5 mL - 57 mg/5 mL, 75 mL bottle, 1 count, NDC 62135-0094-75
    • Amoxicillin and Clavulanate oral powder for suspension, Chartwell, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 62135-0095-13
    • Amoxicillin and Clavulanate oral powder for suspension, Chartwell, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 62135-0095-75
    • Amoxicillin and Clavulanate oral tablet, Chartwell, 500 mg/125 mg, 20 count, NDC 62135-0091-20
    • Amoxicillin and Clavulanate oral tablet, Chartwell, 875 mg/125 mg, 20 count, NDC 62135-0092-20
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00143-9981-01
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9981-75
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00143-9982-01
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00143-9853-16
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00143-9853-24
    • Amoxicillin and Clavulanate oral extended release tablet, Sandoz, 1000 mg / 62.5 mg, 28 count, NDC 00781-1943-82
    • Amoxicillin and Clavulanate oral extended release tablet, Sandoz, 1000 mg / 62.5 mg, 40 count, NDC 00781-1943-39
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6102-46
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 75 mL bottle, 1 count, NDC 00781-6102-57
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6104-46
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 50 mL bottle, 1 count, NDC 00781-6104-52
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 75 mL bottle, 1 count, NDC 00781-6104-57
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00781-6139-54
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00781-6139-48
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00781-6139-57
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 250 mg / 125 mg, 30 count, NDC 00781-1874-31
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 500 mg / 125 mg, 20 count, NDC 00781-1831-20
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 500 mg / 125 mg, 100 count, NDC 00781-1831-01
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 875 mg / 125 mg, 20 count, NDC 00781-1852-20
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 81964-0203-69
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 81964-0203-54
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 81964-0203-51

Estimated Resupply Dates

    • Hikma has amoxicillin and clavulanate 875 mg/125 mg tablets on allocation. The 200 mg-28.5 mL/5 mL in 50 mL bottles, 400 mg-57 mg/5 mL in 50 mL and 75 mL bottles, and 600 mg-42.9 mg/5 mL oral powder for suspension in 75 mL bottles are also on allocation.
    • Sandoz has amoxicillin and clavulanate 200 mg-28.5 mg/5 mL in 50 mL bottles on back order and the company cannot estimate a release date.
    • Teva has most amoxicillin and clavulanate available until current inventory is depleted. Products will be discontinued over the next few months as remaining stock is exhausted. The 200 mg/28.5 mg tablets and 500 mg/125 mg tablets in 20 count bottles are temporarily unavailable.

Updated

Updated September 28, 2026 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 18, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2026, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT